Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02381977

Acronym

PANGEA

Enrollment

922

Registered

2015-03-06

Start date

2011-11-30

Completion date

2014-09-30

Last updated

2015-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Mass, Cardiac Arrest, Hydrocephalus, Spinal Cord Disease, Status Epilepticus, Stroke, Traumatic Brain Injury

Brief summary

PANGEA is an international prospective point prevalence study to describe the epidemiology, interventions, and outcomes in children with acute critical brain disease.

Interventions

OTHERNo intervention

Study design

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

7 Days to 17 Years

Healthy volunteers

Inclusion criteria

1. Children aged 7 days to 17 years inclusively and admitted to an ICU (ICU can be classified as general, cardiac, trauma, etc). 2. Children with acute or acute on chronic neurologic disease that occurred just prior to hospital admission or occurred during the hospital admission. 3. Acute neurologic disease is secondary to TBI, stroke, brain mass, hydrocephalus, cardiac arrest, status epilepticus, CNS infection/inflammation, or spinal cord injury.

Exclusion criteria

1. Children with acute perinatal neurologic disease. 2. Children with isolated chronic brain injury and no acute neurologic disease.

Design outcomes

Primary

Measure	Time frame
Prevalence of acute brain insult	4 days over a 1 year period

Secondary

Measure	Time frame
Mortality	Hospital discharge or 3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026